Orchestra BioMed Secures Ligand Funding for Pivotal Trials
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) received a $15 million investment from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) tied to the company’s ongoing cardiovascular device trials, completing …
Orchestra BioMed Secures Ligand Funding for Pivotal Trials Read More